- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07718984
Treatment of Fibromyalgia and PTSD With Live and Inactive Vagus Nerve Stimulation With PEPC (SWIFT-RELIEVE)
SWIFT-RELIEVE : Simultaneous Treatment of Widespread Pain In Fibromyalgia and PTSD: Randomized Evaluation of Live vs. Inactive Electrical VNS With PE-PC
Fibromyalgia (FM) pain and PTSD are highly prevalent and comorbid with associated increased risk of negative physical and mental health outcomes, including higher risk for opioid use and suicide. This project is designed to determine the effects of a 4 week trial of a device for pain management [transauricular nerve stimulation (tAN)] on pain interference and intensity [Pain, Enjoyment, and Activity General Scale (PEG)] and PTSD. The investigators will also examine how this impacts the Veterans by examining heart rate variability (HRV) as a stress response related biomarker. The investigators plan to randomize 180 Veterans (estimate up to 360 enrolled) with co-morbid FM and PTSD across pain integrated care and PTSD sites in this prospective study and compare: 1) active tAN for pain + Prolonged Exposure in Primary Care (PE-PC) and 2) sham tAN + PE-PC. Study includes 4 weeks of randomized treatment and 4 weeks of voluntary open label treatment. Veterans are assessed (self report & interview measures, heart rate variability by wearable device) at Intake, Baseline/Post Run-In, Week 2, Week 4, Week 8 and 4 month follow-up. The investigators plan to retain data after the study for potential future use in research.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The investigators' goal is to test whether providing simultaneous non-drug treatments for both FM and PTSD improves symptom impact on both conditions. tAN, a non-invasive neuromodulatory technique applied to the auricular branch of the vagus and trigeminal nerves, has preliminary efficacy in reducing chronic pain and reducing PTSD severity in Veterans with PTSD and in an opioid withdrawal population. PE-PC is a form of Prolonged Exposure, a gold standard treatment for PTSD, that is designed for integrated care and effectively reduces PTSD severity. In addition, tAN applied with the proposed device significantly reduced PCL-5 scores by 35% from baseline to Day 5 in adults withdrawing from opioid. Within this high-risk comorbid population, adding a non-opioid pain intervention provided within the context of effective PTSD treatment promises to increase impact on both pain and PTSD. The combination requires minimal additional 'in clinic' time, may be provided in-home or via telehealth, and each is available in VA standard care. Study results can inform implementation for this combined intervention and speed its use in clinics. Thus, more Veterans will have access to effective care for FM and PTSD, supporting a priority of POU-AMP and the VA National Strategy for Preventing Suicide (2018). In summary, the investigators will examine whether pain is reduced with PTSD treatment in FM, and whether addition of tAN can augment this effect compared to sham.
Design: The investigators will randomize 180 Veterans with co-morbid FM and PTSD from across AVAHCS to receive: 1) tAN for pain + PE-PC or 2) sham tAN + PE-PC. tAN administered daily for 2 hours for 4 weeks. PE-PC is provided in six 30-minute sessions up to 3 times per week. Assessments will be collected at Intake, Baseline/Post Run-In, Week 2, Week 4, and [4 month follow-up]. Primary outcome will be posttreatment (week 4) Pain, Enjoyment and General Activity Scale (PEG). Secondary outcomes include Fibromyalgia Impact Questionnaire Revised (FIQR), Polysymptomatic Distress Scale (PSD), PTSD (PCL-5 weekly version). Biomarker analysis will examine the association of HRV [(baseline & trauma cued).
Aim (1): Examine additive efficacy of 1) tAN+PE-PC and 2) sham tAN+PE-PC on FM-related pain interference and intensity in the context of PE-PC for PTSD [Primary Outcome: PEG scale and PTSD symptom severity [Secondary Outcome: PCL5, weekly].
Hypothesis 1a: tAN+PE-PC will result in larger reductions in pain interference and intensity than sham tAN+PE-PC ([Baseline] to Week 4). Differences will be maintained at [4-month follow-up].
Hypothesis 1b: tAN+PE-PC will result in larger reductions in PTSD severity than sham tAN+PE-PC ([Baseline] to Week 4). Differences will be maintained at [4-month follow-up].
Exploratory Aim: Evaluate changes in HRV (baseline & trauma cued) as a biomarker of response associated with FM-related pain and PTSD severity improvement in tAN+PE-PC and sham tAN+PE-PC.
Exploratory Hypothesis: tAN+PE-PC will result in greater change in HRV compared to sham+PE-PC. This proposal targets the Pain and Opioid Use Actively Managed Portfolio (POU-AMP) research priority of pragmatic clinical trials for treatment of painful conditions using non-pharmacological approaches. The long-term objective is improving Veteran health through focused combined intervention for FM and PTSD.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Sheila A Rauch, PhD
- Número de telefone: 3122 (404) 621-3122
- E-mail: Sheila.Rauch@va.gov
Locais de estudo
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30033-4004
- Atlanta VA Medical and Rehab Center, Decatur, GA
-
Investigador principal:
- Anna Woodbury, MD
-
Contato:
- Sheila A Rauch, PhD
- Número de telefone: 3122 (404) 621-3122
- E-mail: Sheila.Rauch@va.gov
-
Investigador principal:
- Sheila A.M. Rauch, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subjects must be any era Veterans reporting fibromyalgia (FM) and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist for DSM-5 (PCL-5) ≥ 28; FM confirmed with ACR Diagnostic Criteria and pain score at least 4/10 for 3 months
- Subjects must speak English
- If subjects are taking psychotropic medication, 2-weeks on stable dose prior to enrollment and agreement to maintain current medications until after the 4-month follow-up visit
Exclusion Criteria:
- Subjects must not have other primary clinical issues that would interfere with fibromyalgia (FM) or post-traumatic stress disorder (PTSD) treatment such as recent stroke or severe heart disease
- Subjects must not have a level of suicide risk that requires intervention as determined by item 9 on PHQ-9 with follow-up risk assessment by study staff
- Subjects must not have severe cognitive impairment that interferes with PE-PC (unable to retain information in acute interaction)
- Subjects must not have unmanaged psychosis or bipolar disorder
- Subjects must not have moderate to severe substance use disorder in the past 8 weeks
- Subjects must not be currently receiving talk therapy for trauma-related symptoms or fibromyalgia (FM)
- Subjects must not be currently pregnant or lactating given risk of pre-term labor and interference of oxytocin with vagus nerve stimulation (VNS) effects
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: taVNS plus PEPC
Transauricular nerve stimulation (tAN) provided for 2 hours per day for weeks. Frequency: 25 Hz on inner region (ABVN), 100Hz on outer region (ATN), Pulse width: 250 µs, Duty cycle: 5 minutes on, 10 second off. Stimulation is combined with 6, 30 minute sessions on Processing Emotions in Primary Care (PEP) brief PTSD psychotherapy provided over 4 weeks. |
The research version of Spark's Sparrow Ascent for vagus and trigeminal nerve stimulation provided through a sticker that attaches to the ear. This device allows the patient to self apply the device in a home setting. It is FDA cleared and available in VA. Stimulation is combined with 6, 30 minute sessions on Processing Emotions in Primary Care (PEP) brief PTSD psychotherapy provided over 4 weeks.
Outros nomes:
|
|
Comparador Falso: Sham plus PEPC
Sham will use the same device and schedule with a brief individualized suprasensory stimulation followed by a ramp down over 2 minutes. Sham is combined with 6, 30 minute sessions on Processing Emotions in Primary Care (PEP) brief PTSD psychotherapy provided over 4 weeks. |
Same device as active condition but programmed with sham parameters including suprasensory stimulation followed by ramp down. Sham is combined with 6, 30 minute sessions on Processing Emotions in Primary Care (PEP) brief PTSD psychotherapy provided over 4 weeks.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain Intensity [Pain, Enjoyment, and General Activity Scale (PEG)]
Prazo: Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Single item rating past week average intensity of pain on a scale from 0 (none) to 10 (As bad as I can imagine) |
Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
|
Pain Interference with Enjoyment [Pain, Enjoyment, and General Activity Scale (PEG)]
Prazo: Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Single item rating of average pain interference with enjoyment of life over the past week on a 0 (no interference) to 10 (completely interfered). |
Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
|
Pain Interference with Activity [Pain, Enjoyment, and General Activity Scale (PEG)]
Prazo: Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Single item rating of average pain interference in general activity over the past week on a 0 (no interference) to 10 (completely interfered). |
Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Post-traumatic stress disorder (PTSD) Checklist for DSM 5 (PCL-5)
Prazo: Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Total sum of each of 20 items covering PTSD symptom ratings for the past week each scored on a 0 (not al all) to 4 (extremely) scale. Total score ranges from 0 to 80. |
Intake, Baseline, Week 2, Week 4, Week 8, 4 month followup
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sheila A.M. Rauch, PhD, Atlanta VA Medical and Rehab Center, Decatur, GA
- Investigador principal: Anna Woodbury, MD, Atlanta VA Medical and Rehab Center, Decatur, GA
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Relacionados a Traumas e Estressores
- Manifestações Neurológicas
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Doenças Musculares
- Transtornos Mentais, Desordem Mental
- Doenças Neuromusculares
- Doenças Reumáticas
- Transtornos de Estresse Traumático
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Dor
- Fibromialgia
- Transtornos de Estresse Pós-Traumático
Outros números de identificação do estudo
- RRDA-009-25W
- 1-I01-RD-000404-01-A2 (Número de outro subsídio/financiamento: eRA Number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
A deidentified dataset will be available with publication per policy of the journal on publication or upon appropriate request after all primary statement of work analyses are published.
Prazo de Compartilhamento de IPD
Upon publication if required and after publication of all primary statement of work analyses upon appropriate request.
Critérios de acesso de compartilhamento IPD
Data will available from request to the principal investigator after all publications are released.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .